Trial Profile
Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Vismodegib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 08 Mar 2024 Planned End Date changed from 1 Nov 2009 to 7 Mar 2025.
- 28 Jun 2018 Status changed from completed to active, no longer recruiting.
- 27 Jun 2018 Status changed from active, no longer recruiting to completed.